Literature DB >> 3492538

Anti-receptor anti-MHC cytotoxic T lymphocytes: their role in the resistance to graft vs host reaction.

K Kosmatopoulos, D S Algara, S Orbach-Arbouys.   

Abstract

Specific resistance to local graft vs host reaction (GvHR) observed in F1 hybrids pretreated s.c., i.p., or i.v. with parent strain spleen cells has been explained as being due to cytotoxic cells induced in these pretreated F1 hybrids and directed against cells bearing receptors that recognize the major histocompatibility complex (MHC) alloantigens of the opposite parent strain (anti-receptor anti-MHC cytotoxic T lymphocytes; CTL). These anti-receptor anti-MHC CTL, however, have never been detected directly in popliteal lymph nodes (PLN), which develop a specific resistance to GvHR. In this paper, we describe the detection of anti-receptor anti-D2 cytotoxic activity in both right and left PLN of B6D2F1 hybrids injected s.c. in the right footpad only with B6 spleen cells. This cytotoxic activity appears 4 days after the injection of B6 cells and diminishes by day 7. It is mediated by a Thy-1+, L3T4-, Lyt-2+ cell of B6D2F1 origin and induced by the injection of either Thy-1+L3T4+Lyt-2- or Thy-1+L3T4-Lyt-2+ B6 spleen cells. The anti-receptor anti-D2 CTL activity is not observed in PLN of B6D2F1 hybrids pretreated i.p. or i.v. with B6 spleen cells. Our results demonstrate that anti-receptor anti-MHC CTL can fully explain the specific resistance to GvHR induced by the s.c. pretreatment of F1 hybrids with parent strain spleen cells. Their role, however, in the resistance to GvHR observed in F1 hybrids i.v. or i.p. pretreated is far from being entirely proven.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492538

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE.

Authors:  I Puliaeva; R Puliaev; C S Via
Journal:  Autoimmun Rev       Date:  2008-08-24       Impact factor: 9.754

2.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

3.  Fas expression on antigen-specific T cells has costimulatory, helper, and down-regulatory functions in vivo for cytotoxic T cell responses but not for T cell-dependent B cell responses.

Authors:  Irina Puliaeva; Roman Puliaev; Andrei Shustov; Mark Haas; Charles S Via
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

4.  Graft-versus-host resistance induced by class II major histocompatibility complex-specific T cell clones.

Authors:  P V Lehmann; K Drexler; M Tary-Lehmann; F Falcioni; U Hurtenbach; Z A Nagy
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

5.  Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells).

Authors:  M I Perez; R L Edelson; L John; L Laroche; C L Berger
Journal:  Yale J Biol Med       Date:  1989 Nov-Dec

6.  Generation of T cells with lytic specificity for atypical antigens. III. Priming F1 animals with antigen-bearing cells also having reactivity for host alloantigens allows for potent lytic T cell responses.

Authors:  J D Davies; D H Wilson; D B Wilson
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

7.  Generation of T cells with lytic specificity for atypical antigens. I. A mitochondrial antigen in the rat.

Authors:  J D Davies; D H Wilson; E Hermel; K F Lindahl; G W Butcher; D B Wilson
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

8.  Regulation of autoimmunity and donor cell engraftment by recipient Lyt-2+ cells during the graft-versus-host reaction.

Authors:  S E Harper; J R Roubinian; W E Seaman
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.